Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway

被引：33

作者：

Wakabayashi, Grace ^{[1
]}

Lee, Yu-Ching ^{[2
]}

Luh, Frank ^{[3
]}

Kuo, Chun-Nan ^{[4
,5
,6
]}

Chang, Wei-Chiao ^{[4
,5
,6
]}

Yen, Yun ^{[7
]}

机构：

[1] Taipei Med Univ, 250 Wu Hsing St, Taipei 110, Taiwan

[2] Taipei Med Univ, Ctr Canc Transnat Res, 250 Wu Hsing St, Taipei 110, Taiwan

[3] Sino Amer Canc Fdn, 668 Arrow Grand Circle,Suite 101, Covina, CA 91722 USA

[4] Taipei Med Univ, Dept Clin Pharm, Sch Pharm, 250 Wu Hsing St, Taipei 110, Taiwan

[5] Wan Fang Hosp, Dept Pharm, Integrat Therapy Ctr Gastroenterol Canc, 250 Wu Hsing St, Taipei 110, Taiwan

[6] Taipei Med Univ, 250 Wu Hsing St, Taipei 110, Taiwan

[7] Taipei Med Univ, PhD Program Canc Biol & Drug Discovery, 250 Wu Hsing St, Taipei 110, Taiwan

来源：

JOURNAL OF BIOMEDICAL SCIENCE | 2019年 / 26卷 / 01期

关键词：

Checkpoint inhibitor; Cancer immunotherapy; PD-1; PD-L1; signaling; TUMOR MUTATIONAL BURDEN; OPEN-LABEL; ADVANCED MELANOMA; INVESTIGATORS CHOICE; COMBINED NIVOLUMAB; COLORECTAL-CANCER; B7; FAMILY; T-CELLS; IPILIMUMAB; PEMBROLIZUMAB;

D O I：

10.1186/s12929-019-0588-8

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Dramatic advances in immune therapy have emerged as a promising strategy in cancer therapeutics. In addition to chemotherapy and radiotherapy, inhibitors targeting immune-checkpoint molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) demonstrate impressive clinical benefits in clinical trials. In this review, we present background information about therapies involving PD-1/PD-L1 blockade and provide an overview of current clinical trials. Furthermore, we present recent advances involving predictive biomarkers associated with positive therapeutic outcomes in cancer immunotherapy.

引用

页数：13

共 109 条

[1] Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series
Akella, Padmastuti
Loganathan, Sundaravadivel
Jindal, Vishal
Akhtar, Jamal
Lal, Amos
[J]. RESPIRATORY MEDICINE CASE REPORTS, 2019, 26 : 17 - 22
[2] Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Anagnostou, Valsamo
Smith, Kellie N.
Forde, Patrick M.
Niknafs, Noushin
Bhattacharya, Rohit
White, James
Zhang, Theresa
Adleff, Vilmos
Phallen, Jillian
Wali, Neha
Hruban, Carolyn
Guthrie, Violeta B.
Rodgers, Kristen
Naidoo, Jarushka
Kang, Hyunseok
Sharfman, William
Georgiades, Christos
Verde, Franco
Illei, Peter
Li, Qing Kay
Gabrielson, Edward
Brock, Malcolm V.
Zahnow, Cynthia A.
Baylin, Stephen B.
Scharpf, Robert B.
Brahmer, Julie R.
Karchin, Rachel
Pardoll, Drew M.
Velculescu, Victor E.
[J]. CANCER DISCOVERY, 2017, 7 (03) : 264 - 276
[3] [Anonymous], 2012, LIVERTOX CLIN RES IN
[4] Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial
Ascierto, Paolo A.
Long, Georgina V.
Robert, Caroline
Brady, Benjamin
Dutriaux, Caroline
Di Giacomo, Anna Maria
Mortier, Laurent
Hassel, Jessica C.
Rutkowski, Piotr
McNeil, Catriona
Kalinka-Warzocha, Ewa
Savage, Kerry J.
Hernberg, Micaela M.
Lebbe, Celeste
Charles, Julie
Mihalcioiu, Catalin
Chiarion-Sileni, Vanna
Mauch, Cornelia
Cognetti, Francesco
Ny, Lars
Arance, Ana
Svane, Inge Marie
Schadendorf, Dirk
Gogas, Helen
Saci, Abdel
Jiang, Joel
Rizzo, Jasmine
Atkinson, Victoria
[J]. JAMA ONCOLOGY, 2019, 5 (02) : 187 - 194
[5] Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
Bagley, Stephen J.
Kothari, Shawn
Aggarwal, Charu
Bauml, Joshua M.
Alley, Evan W.
Evans, Tracey L.
Kosteva, John A.
Ciunci, Christine A.
Gabriel, Peter E.
Thompson, Jeffrey C.
Stonehouse-Lee, Susan
Sherry, Victoria E.
Gilbert, Elizabeth
Eaby-Sandy, Beth
Mutale, Faith
DiLullo, Gloria
Cohen, Roger B.
Vachani, Anil
Langer, Corey J.
[J]. LUNG CANCER, 2017, 106 : 1 - 7
[6] Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, DL
Wherry, EJ
Masopust, D
Zhu, BG
Allison, JP
Sharpe, AH
Freeman, GJ
Ahmed, R
[J]. NATURE, 2006, 439 (7077) : 682 - 687
[7] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J.
de Wit, R.
Vaughn, D. J.
Fradet, Y.
Lee, J. -L.
Fong, L.
Vogelzang, N. J.
Climent, M. A.
Petrylak, D. P.
Choueiri, T. K.
Necchi, A.
Gerritsen, W.
Gurney, H.
Quinn, D. I.
Culine, S.
Sternberg, C. N.
Mai, Y.
Poehlein, C. H.
Perini, R. F.
Bajorin, D. F.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
[8] DNA repair defects and implications for immunotherapy
Bever, Katherine M.
Le, Dung T.
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (10) : 4236 - 4242
[9] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
Borghaei, H.
Paz-Ares, L.
Horn, L.
Spigel, D. R.
Steins, M.
Ready, N. E.
Chow, L. Q.
Vokes, E. E.
Felip, E.
Holgado, E.
Barlesi, F.
Kohlhaeufl, M.
Arrieta, O.
Burgio, M. A.
Fayette, J.
Lena, H.
Poddubskaya, E.
Gerber, D. E.
Gettinger, S. N.
Rudin, C. M.
Rizvi, N.
Crino, L.
Blumenschein, G. R.
Antonia, S. J.
Dorange, C.
Harbison, C. T.
Finckenstein, F. Graf
Brahmer, J. R.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
[10] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
Carbone, D. P.
Reck, M.
Paz-Ares, L.
Creelan, B.
Horn, L.
Steins, M.
Felip, E.
van den Heuvel, M. M.
Ciuleanu, T. -E.
Badin, F.
Ready, N.
Hiltermann, T. J. N.
Nair, S.
Juergens, R.
Peters, S.
Minenza, E.
Wrangle, J. M.
Rodriguez-Abreu, D.
Borghaei, H.
Blumenschein, G. R.
Villaruz, L. C.
Havel, L.
Krejci, J.
Corral Jaime, J.
Chang, H.
Geese, W. J.
Bhagavatheeswaran, P.
Chen, A. C.
Socinski, M. A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) : 2415 - 2426

← 1 2 3 4 5 6 7 8 9 10 →